Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PR1 Vaccine with or without Interferon in CML
NCT00415857Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2006
- Primary completion
- Sep 2013
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PR1 leukemia peptide vaccine in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2006; status: terminated.
02
Drugs
PR1 leukemia peptide vaccine
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00415857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00415857.